Skip to main content




As a young Philadelphia lawyer in 1969 Steve Goodman began representing emerging companies.  At that time, law firms and the banking industry largely dismissed the start-up sector.  Mr. Goodman believed in encouraging entrepreneurs and the importance of developing innovation.  He understood that economic growth and innovation in the Mid-Atlantic region would be accelerated by fostering early-stage businesses.  He is credited with creating the Emerging Growth law practice segment on the East Coast.  Everyone in the private equity space up and down the East Coast was aware of Steve's enormous contribution to the space from seed-stage investors to Safeguard Scientifics, the largest VC firm in the area. 

Over the course of his amazing career at Morgan Lewis leading to the creation of countless new business ventures, Mr. Goodman was nicknamed the 
Godfather of Philadelphia Startups.  Keiretsu Forum Mid-Atlantic is honored to have received Steve's permission to use his name as part of this prestigious annual award and it is in the spirit of Steve’s vision and keen skills with emerging businesses that Keiretsu Forum Mid-Atlantic will continue to honor his legacy.   Steve passed away on March 2, 2018 leaving a void in the ecosystem that will likely never be filled. 




Back in 2011 when we created the Philadelphia Chapter of Keiretsu Forum Mid-Atlantic we met with Steve to discuss the Keiretsu model and process and asked for his advice and insight on how to best present this new angel investing model to the region.  Steve immediately pointed out the obvious advantage of having a national footprint for syndication and collaboration as well as the advantage of addressing the later stage A & B round opportunities, a market segment that was not being fully addressed at the time.  He offered us his best wishes and his support in bringing K4-MA to Philadelphia.    


On Wednesday, October 14, 2020, Keiretsu Forum Mid-Atlantic will host their 8th Annual Investor Capital Expo at The Union League of Philadelphia.   The Investor Capital Expo provides a unique format for invited investors and breakthrough startups to converge in meaningful conversations, education, and exchange.  Up to twelve presentations from Series A-B Round entrepreneurs will be evaluated by 200+ accredited angel investors, venture capital professionals, partners, and sponsors.  The accredited investors attending the Expo will vote for and select the 2020 Stephen M. Goodman Most Valued Company Award winner.


2019:  The Stephen M. Goodman Most Valued Company Award went to OtoNexus, the Seattle based company that has raised more than $15 million in angel capital as well as grants from the NIH and NSF.  OtoNexus is working to bring the process of diagnosing ear infections into the 21st century.  Ear infections are the #1 reason for both surgery and antibiotic use in children. Currently, there is a 50% error rate in the diagnosis of middle ear infections in children, leading to an estimated $10-15 billion in annual medical costs in the United States alone. OtoNexus' device shortens treatment time, reduces misdiagnosis, and helps clinicians avoid unnecessary antibiotic use through the innovative use of ultrasound technology.   According to OtoNexus CEO Caitlin Cameron, “we’re proud to be chosen by so many angel investors and Keiretsu Forum members, and appreciate their votes of confidence in supporting the development of a device that should have a profound impact on patients, doctors and ultimately the entire healthcare industry.”  


Runners up for this award included 2nd place gel-e (now Medcura) 
and 3rd place UbiQD.  Medcura is developing a line of advanced hemostatic and wound treatment products that address unmet needs from the operating room to the backyard.  UbiQD, a nanotechnology company based in Los Alamos, New Mexico manufactures high-performance, cadmium-free quantum dots, and composite materials. UbiQD was recently named the winner in the Hyper-Connected Communities category of the 2019 South by Southwest ('SXSW') competition.  


2018:  The 2018 Goodman Award winner, Pittsburgh based Carmell Therapeutics has leveraged the distinction to advance into IND trials.  According to Randy Hubbell, CEO, "the Goodman Award provided validation that we had the right team and a solid plan in place to succeed.  We have been able to use this credibility to shorthand conversations with other investment groups and high-worth individuals that also believe in our plan.  Exposure at Expo and winning the Goodman Award gave us the fuel needed to reach key FDA milestones, create value, and develop a regulator platform to get institutional investments for Phase Three clinical trials.  Having strong partnerships in place with Keiretsu Forum members and Keiretsu Capital has enabled Carmell to build a funding and regulatory strategy that will lead to rapid commercialization.



2017:  In 2017, INDIGO Biosciences was the recipient of this honor.  "The Angel Capital Expo provided INDIGO with a national forum to present the value of the Company.   As the 2017 Goodman Most Valued Company recipient, INDIGO secured over $600,000 in investments from Keiretsu Mid-Atlantic and other angels who attended the event.  The Company surpassed its capital funding target because of the Angel Capital Expo!" -Fred Marroni, CEO INDIGO Biosciences.